

ClinicalTrials.gov Search Results 07/07/2022

	Title	Status	Study Results	Conditions	Interventions	Locations
1	COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> •Covid19 •Vaccine Refusal •Vaccine Hesitancy 	<ul style="list-style-type: none"> •Behavioral: COVID-19 Vaccine Education at the Point of COVID-19 Testing 	<ul style="list-style-type: none"> •Xavier University of Louisiana, New Orleans, Louisiana, United States
2	Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection	Unknown status	No Results Available	<ul style="list-style-type: none"> •COVID-19 	<ul style="list-style-type: none"> •Device: Hyperbaric Oxygen Therapy 	<ul style="list-style-type: none"> •Ochsner Medical Center, New Orleans, Louisiana, United States
3	Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19	No longer available	No Results Available	<ul style="list-style-type: none"> •COVID-19 	<ul style="list-style-type: none"> •Biological: Biological: COVID-19 convalescent plasma 	<ul style="list-style-type: none"> •Tulane Medical Center, New Orleans, Louisiana, United States
4	Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease	Terminated	No Results Available	<ul style="list-style-type: none"> •COVID-19 	<ul style="list-style-type: none"> •Drug: Hydroxychloroquine •Drug: Azithromycin 	<ul style="list-style-type: none"> •University Medical Center New Orleans, New Orleans, Louisiana, United States
5	Estradiol and Progesterone in Hospitalized COVID-19 Patients	Recruiting	No Results Available	<ul style="list-style-type: none"> •Covid19 	<ul style="list-style-type: none"> •Other: Placebo injection and placebo pill •Drug: Estradiol Cypionate 5 MG/ML •Drug: Progesterone 200 MG Oral Capsule 	<ul style="list-style-type: none"> •Tulane University Medical Center, New Orleans, Louisiana, United States
6	Real World Study of COVID-19 in a Flyover Region	Recruiting	No Results Available	<ul style="list-style-type: none"> •Covid19 		<ul style="list-style-type: none"> •Tulane University Medical Center, New Orleans, Louisiana, United States
7	Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19	Terminated	No Results Available	<ul style="list-style-type: none"> •Covid19 	<ul style="list-style-type: none"> •Biological: F-652 •Biological: Placebo 	<ul style="list-style-type: none"> •Tulane University School of Medicine, New Orleans, Louisiana, United States
8	Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate	Recruiting	No Results Available	<ul style="list-style-type: none"> •Covid19 •Vaccine Refusal 	<ul style="list-style-type: none"> •Behavioral: Community health worker engagement 	<ul style="list-style-type: none"> •Tulane University Medical Center, New Orleans, Louisiana, United States
9	Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development	Recruiting	No Results Available	<ul style="list-style-type: none"> •Covid19 		<ul style="list-style-type: none"> •Tulane University Medical Center, New Orleans, Louisiana, United States •University Medical Center New Orleans, New Orleans, Louisiana, United States
10	Outpatient Liquid Aspirin (OLA)	Recruiting	No Results Available	<ul style="list-style-type: none"> •Covid19 	<ul style="list-style-type: none"> •Drug: ASA 	<ul style="list-style-type: none"> •Lsuhscc-No, New Orleans, Louisiana, United States
11	WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> •Covid19 •Cardiovascular Complication •Behavioral Changes 		<ul style="list-style-type: none"> •Tulane University, TRIAD Center, New Orleans, Louisiana, United States •Tulane University, New Orleans, Louisiana, United States
12	Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)	Recruiting	No Results Available	<ul style="list-style-type: none"> •COVID-19 •Corona Virus Infection •Wuhan Coronavirus •Prophylaxis •Healthcare Worker •Sars-CoV2 •Hydroxychloroquine 	<ul style="list-style-type: none"> •Drug: Hydroxychloroquine •Drug: Placebo 	<ul style="list-style-type: none"> •Lafayette General Medical Center, Lafayette, Louisiana, United States •University Hospital and Clinics, Lafayette, Louisiana, United States
13	Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients	Completed	No Results Available	<ul style="list-style-type: none"> •Covid19 •Corona Virus Infection •Autoimmune Diseases •Coagulation Disorder, Blood 	<ul style="list-style-type: none"> •Device: Narrow Band ultraviolet B-Band Light •Device: non Narrow Band ultraviolet B-Band Light 	<ul style="list-style-type: none"> •West Jefferson Medical Center and LSUHSC-NO, New Orleans, Louisiana, United States
14	Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19	Unknown status	No Results Available	<ul style="list-style-type: none"> •COVID-19 	<ul style="list-style-type: none"> •Drug: Hydroxychloroquine •Drug: Indomethacin •Drug: Zithromax Oral Product 	<ul style="list-style-type: none"> •Perseverance Research Center, Scottsdale, Arizona, United States •Covidcraz 19, Llc, New Orleans, Louisiana, United States
15	Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis	Recruiting	No Results Available	<ul style="list-style-type: none"> •Sepsis Syndrome 	<ul style="list-style-type: none"> •Biological: MMR vaccine 	<ul style="list-style-type: none"> •Clinical and Translational Research Center, New Orleans, Louisiana, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
16	Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes	Completed	No Results Available	<ul style="list-style-type: none">•Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection•Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types		<ul style="list-style-type: none">•Ochsner Clinic Foundation, New Orleans, Louisiana, United States•Atlantic Health System, Morristown, New Jersey, United States
17	SQulSH-COVID: A Pilot Study	Active, not recruiting	No Results Available	<ul style="list-style-type: none">•Sepsis•COVID-19		<ul style="list-style-type: none">•Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States
18	Transplacental Transmission of RSV (TTRSV)	Recruiting	No Results Available	<ul style="list-style-type: none">•SARS CoV 2 Infection•Respiratory Syncytial Virus (RSV)•Bronchiolitis•Asthma		<ul style="list-style-type: none">•Tulane University Lakeside Hospital, Metairie, Louisiana, United States•Ochsner Baptist Hospital, New Orleans, Louisiana, United States
19	GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)	Recruiting	No Results Available	<ul style="list-style-type: none">•SARS-CoV 2•Infection	<ul style="list-style-type: none">•Drug: GLS-1200•Drug: Placebo	<ul style="list-style-type: none">•Sinus and Nasal Specialists of Louisiana, Baton Rouge, Louisiana, United States•University of Pennsylvania, Philadelphia, Pennsylvania, United States•Conroe Willis Medical Reasearch, Conroe, Texas, United States
20	Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19	Active, not recruiting	No Results Available	<ul style="list-style-type: none">•Coronavirus Infections•Pneumonia, Viral•Acute Respiratory Distress Syndrome	<ul style="list-style-type: none">•Drug: Nitric Oxide	<ul style="list-style-type: none">•Providence HealthCare Network, Anchorage, Alaska, United States•Louisiana State University Health Shreveport, Shreveport, Louisiana, United States•Massachusetts General Hospital, Boston, Massachusetts, United States
21	Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)	Terminated	No Results Available	<ul style="list-style-type: none">•COVID-19•Viral Respiratory Illnesses	<ul style="list-style-type: none">•Drug: Nitazoxanide•Drug: Placebo•Dietary Supplement: Vitamin Super B-Complex	<ul style="list-style-type: none">•The Chappel Group Research, Kissimmee, Florida, United States•Clinical Trial Specialists, Inc., Acworth, Georgia, United States•Centex Studies, Inc., Lake Charles, Louisiana, United States•Centex Studies, Inc., Houston, Texas, United States
22	NCI COVID-19 in Cancer Patients, NCCAPS Study	Active, not recruiting	No Results Available	<ul style="list-style-type: none">•COVID-19 Infection•Hematopoietic and Lymphoid Cell Neoplasm•Malignant Solid Neoplasm•Metastatic Malignant Solid Neoplasm	<ul style="list-style-type: none">•Procedure: Biospecimen Collection•Other: Data Collection•Other: Quality-of-Life Assessment•Other: Questionnaire Administration	<ul style="list-style-type: none">•University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States•Veterans Administration Medical Center - Birmingham, Birmingham, Alabama, United States•USA Health Strada Patient Care Center, Mobile, Alabama, United States•Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States•Anchorage Radiation Therapy Center, Anchorage, Alaska, United States•Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States•Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States•Alaska Women's Cancer Care, Anchorage, Alaska, United States•Anchorage Oncology Centre, Anchorage, Alaska, United States•Katmai Oncology Group, Anchorage, Alaska, United States•and 931 more

	Title	Status	Study Results	Conditions	Interventions	Locations
23	A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants	Active, not recruiting	Has Results	<ul style="list-style-type: none"> •Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol 	<ul style="list-style-type: none"> •Biological: Ad26.COV2.S •Other: Placebo 	<ul style="list-style-type: none"> •Synexus Clinical Research US, Inc, Birmingham, Alabama, United States •University of Alabama Birmingham, Birmingham, Alabama, United States •Alabama Vaccine Research Clinic at UAB, Birmingham, Alabama, United States •Optimal Research, Huntsville, Alabama, United States •Synexus Clinical Research US, Inc, Glendale, Arizona, United States •VA Medical Center, Phoenix, Arizona, United States •Central Phoenix Medical Clinic, Phoenix, Arizona, United States •Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States •Synexus Clinical Research US, Inc, Tucson, Arizona, United States •University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States •and 214 more
24	Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy	Withdrawn	No Results Available	<ul style="list-style-type: none"> •COVID-19 	<ul style="list-style-type: none"> •Drug: Tofacitinib •Other: Placebo 	<ul style="list-style-type: none"> •Hartford Hospital (HH), Hartford, Connecticut, United States •University of Iowa Hospitals & Clinics Investigational Drug Services, Iowa City, Iowa, United States •University of Iowa, Iowa City, Iowa, United States •LSUHSC-Shreveport, Shreveport, Louisiana, United States •Ochsner LSU Health Shreveport Academic Medical Center, Shreveport, Louisiana, United States •University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
25	A Study to Evaluate the Safety and Efficacy of MSTT1041A (AsteGolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia	Completed	Has Results	<ul style="list-style-type: none"> •COVID-19 Pneumonia 	<ul style="list-style-type: none"> •Drug: MSTT1041A •Drug: MSTT1041A-matched Placebo •Drug: UTTR1147A •Drug: UTTR1147A-matched Placebo 	<ul style="list-style-type: none"> •University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States •eStudySite - Chula Vista - PPDS, Chula Vista, California, United States •eStudySite, La Mesa, California, United States •Torrance Memorial Medical Center, Torrance, California, United States •Denver Health Medical Center, Denver, Colorado, United States •Bay Pines VA Medical Center - NAVREF, Bay Pines, Florida, United States •WellStar Research Institute, Marietta, Georgia, United States •DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS, Alexandria, Louisiana, United States •MedPharmics, Metairie, Louisiana, United States •Southeast Louisiana Veterans Health Care System - NAVREF, New Orleans, Louisiana, United States •and 31 more

	Title	Status	Study Results	Conditions	Interventions	Locations
26	Understanding the Long-term Impact of COVID-19 in Adults	Recruiting	No Results Available	•SARS-CoV2 Infection		<ul style="list-style-type: none">•University of Alabama at Birmingham (Pregnancy Cohort), Birmingham, Alabama, United States•University of Alabama at Birmingham, Birmingham, Alabama, United States•University of South Alabama, Mobile, Alabama, United States•Banner University Medical Center (BUMC) - Phoenix, Phoenix, Arizona, United States•University of Arizona, Tucson, Arizona, United States•Cedars-Sinai Medical Center, Los Angeles, California, United States•University of California San Francisco (Pregnancy Cohort), San Francisco, California, United States•University of California, San Francisco (UCSF), San Francisco, California, United States•Stanford University, Stanford, California, United States•Denver Health and Hospital Authority, Denver, Colorado, United States•and 76 more
27	Adaptive COVID-19 Treatment Trial 3 (ACTT-3)	Completed	Has Results	•COVID-19	<ul style="list-style-type: none">•Drug: Interferon beta-1a•Other: Placebo•Drug: Remdesivir	<ul style="list-style-type: none">•University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States•UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States•University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States•University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States•University of California Irvine Medical Center - Infectious Disease, Orange, California, United States•VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States•Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States•University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States•Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States•University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States•and 54 more

	Title	Status	Study Results	Conditions	Interventions	Locations
28	Adaptive COVID-19 Treatment Trial 2 (ACTT-2)	Completed	Has Results	•COVID-19	•Other: Placebo •Drug: Remdesivir •Drug: Baricitinib	•University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States •University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States •University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States •University of California Irvine Medical Center - Infectious Disease, Orange, California, United States •VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States •Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States •University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States •Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States •University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States •Cedars Sinai Medical Center, West Hollywood, California, United States •and 61 more
29	Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19	Completed	No Results Available	•Covid-19	•Drug: Abivertinib •Other: Standard of Care	•MedStar Washington Hospital Center, Washington, District of Columbia, United States •Teradan Clinical Trials, Brandon, Florida, United States •Alexandria Cardiology Clinic, Alexandria, Louisiana, United States •Clinical Trials of SWLA, Lake Charles, Louisiana, United States •Quality Clinical Research, Omaha, Nebraska, United States •Memorial Hermann Memorial City Hospital, Houston, Texas, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
30	ACTIV-2: A Study for Outpatients With COVID-19	Active, not recruiting	No Results Available	<ul style="list-style-type: none">•Coronavirus•Covid19	<ul style="list-style-type: none">•Biological: bamlanivimab•Drug: Placebo (IV)•Biological: BR11-196/BR11-198•Biological: AZD7442 (IV)•Biological: AZD7442 (IM)•Drug: SNG001•Drug: Camostat•Drug: Placebo (IM)•Drug: Placebo (Inhaled solution)•Drug: Placebo (oral tablet)•and 5 more	<ul style="list-style-type: none">•Pinnacle Research Group (Site 1082), 321 E. 10th Street, Anniston, Alabama, United States•North Alabama Research Center LLC (Site 1194), 721 W. Market St., Ste. B, Athens, Alabama, United States•University of Alabama at Birmingham (Site 1005), 908 20th Street South, Birmingham, Alabama, United States•Cullman Clinical Trials (Site 1140), 501 Clark St. NE., Cullman, Alabama, United States•Jasper Summit Research, LLC. (Site 1056), 1280 Summit, Jasper, Alabama, United States•Absolute Clinical Research, LLC. (Site 1186), 7725 North 43rd Avenue, Ste. 211, Phoenix, Arizona, United States•University of Arizona (Site 1043), 1501 N. Campbell Ave., Rm. 6410, Tucson, Arizona, United States•Omnibus Clinical Research (Site 1253), 3340 W. Ball Road, Ste. I, Anaheim, California, United States•Franco A. Felizarta MD (Site 1174), 3535 San Dimas St., Bakersfield, California, United States•Clearview Medical Research LLC. (Site 1251), 2714 Hidaway Ave., Ste. 103, Canyon Country, California, United States•and 241 more
31	To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants #12 Years of Age.	Recruiting	No Results Available	<ul style="list-style-type: none">•SARS-CoV-2 Infection•COVID-19	<ul style="list-style-type: none">•Biological: BNT162b2•Other: Placebo•Biological: BNT162b2 OMI•Biological: Combination BNT162b2 and BNT162b2 OMI•Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI	<ul style="list-style-type: none">•North Alabama Research Center, Athens, Alabama, United States•Accel Research Sites - Birmingham Clinical Research Unit, Birmingham, Alabama, United States•Medical Affiliated Research Center (MARC), Huntsville, Alabama, United States•Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States•Johns Hopkins Center for American Indian Health, Chinle, Arizona, United States•Hope Research Institute, Phoenix, Arizona, United States•The Pain Center of Arizona, Phoenix, Arizona, United States•HOPE Research Institute, Phoenix, Arizona, United States•Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States•Johns Hopkins Center for American Indian Health, Whiteriver, Arizona, United States•and 147 more

	Title	Status	Study Results	Conditions	Interventions	Locations
32	Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).	Recruiting	No Results Available	•COVID-19	•Drug: PF-07321332 •Drug: Ritonavir •Drug: Placebo	•Cahaba Research Inc, Birmingham, Alabama, United States •Cahaba Research, Inc., Birmingham, Alabama, United States •Cahaba Research, Inc., Pelham, Alabama, United States •The Institute for Liver Health dba Arizona Clinical Trials, Mesa, Arizona, United States •The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States •KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States •Hope Clinical Research, Canoga Park, California, United States •Lightship, El Segundo, California, United States •Ascada Research, Fullerton, California, United States •eStudySite, La Mesa, California, United States •and 362 more
33	A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection	Recruiting	No Results Available	•COVID-19	•Drug: PF-07321332 •Drug: Placebo for PF-07321332 •Drug: Placebo for Ritonavir •Drug: Ritonavir	•Cahaba Research, Inc., Pelham, Alabama, United States •The Institute for Liver Health dba Arizona Clinical Trials, Mesa, Arizona, United States •The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States •KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States •Hope Clinical Research, Canoga Park, California, United States •Lightship, El Segundo, California, United States •Ascada Health PC, Fullerton, California, United States •Ark Clinical Research, Long Beach, California, United States •American Institute of Research, Los Angeles, California, United States •FOMAT Medical Research, Oxnard, California, United States •and 348 more
34	Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19	Active, not recruiting	No Results Available	•COVID-19	•Drug: casirivimab+imdevimab combination therapy	•Regeneron Study Site, Mesa, Arizona, United States •Regeneron Study Site, Tucson, Arizona, United States •Regeneron Study Site, Tucson, Arizona, United States •Regeneron Study Site, Canoga Park, California, United States •Regeneron Study Site, La Mesa, California, United States •Regeneron Study Site, La Palma, California, United States •Regeneron Study Site 1, Long Beach, California, United States •Regeneron Study Site 2, Long Beach, California, United States •Regeneron Study Site 3, Long Beach, California, United States •Regeneron Study Site, Los Angeles, California, United States •and 104 more

	Title	Status	Study Results	Conditions	Interventions	Locations
35	Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals	Active, not recruiting	No Results Available	<ul style="list-style-type: none">•SARS-CoV-2 Infection•COVID-19	<ul style="list-style-type: none">•Biological: BNT162b1•Biological: BNT162b2•Other: Placebo•Biological: BNT162b2SA	<ul style="list-style-type: none">•North Alabama Research Center, LLC, Athens, Alabama, United States•Birmingham Clinical Research Unit, Birmingham, Alabama, United States•Medical Affiliated Research Center, Huntsville, Alabama, United States•Optimal Research, LLC, Huntsville, Alabama, United States•Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States•Chinle Comprehensive Health Care Facility, Chinle, Arizona, United States•Johns Hopkins Center for American Indian Health, Chinle, Arizona, United States•The Pain Center of Arizona, Phoenix, Arizona, United States•HOPE Research Institute, Phoenix, Arizona, United States•Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States•and 154 more
36	EPIC-Peds: Study of Oral PF-07321332 (Nirmatrelvir)/ Ritonavir in Nonhospitalized COVID-19 Pediatric Patients at Risk for Severe Disease	Recruiting	No Results Available	<ul style="list-style-type: none">•COVID-19	<ul style="list-style-type: none">•Drug: nirmatrelvir•Drug: ritonavir	<ul style="list-style-type: none">•Childrens of Alabama, Birmingham, Alabama, United States•Arkansas Children's Hospital, Little Rock, Arkansas, United States•Children's Hospital Los Angeles, Los Angeles, California, United States•Kaiser Permanente Medical Center Infectious Disease, Los Angeles, California, United States•Life Spring Research Foundation, Miami, Florida, United States•Clinical Site Partners, Inc., Winter Park, Florida, United States•Children's Healthcare of Atlanta - Egleston Hospital, Atlanta, Georgia, United States•SKY Clinical Research Network Group-Blake, Union City, Georgia, United States•Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States•Louisiana State University Health Sciences Shreveport, Shreveport, Louisiana, United States•and 50 more

	Title	Status	Study Results	Conditions	Interventions	Locations
37	Adaptive COVID-19 Treatment Trial (ACTT)	Completed	Has Results	•COVID-19	•Other: Placebo •Drug: Remdesivir	•University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States •University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States •University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States •University of California Irvine Medical Center - Infectious Disease, Orange, California, United States •VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States •University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States •Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States •University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States •Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States •Cedars Sinai Medical Center, West Hollywood, California, United States •and 50 more
38	Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)	Completed	No Results Available	•COVID-19	•Biological: GAMUNEX-C •Drug: Standard Medical Treatment	•Chandler Regional Medical Center, Chandler, Arizona, United States •Southern California Research Center, Coronado, California, United States •University of Illinois at Chicago, Chicago, Illinois, United States •Via Christi Research, Wichita, Kansas, United States •University of Louisville, Louisville, Kentucky, United States •Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States •McLaren Flint, Flint, Michigan, United States •McLaren Health Care-Macomb, Mount Clemens, Michigan, United States •McLaren Health Care Oakland, Pontiac, Michigan, United States •CHI Health, Omaha, Nebraska, United States •and 8 more

	Title	Status	Study Results	Conditions	Interventions	Locations
39	A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness	Completed	Has Results	•COVID-19	•Drug: Bamlanivimab •Drug: Etesevimab •Drug: Placebo •Drug: VIR-7831 •Drug: Bebtelovimab	•University of Alabama at Birmingham, Birmingham, Alabama, United States •The Institute for Liver Health, Mesa, Arizona, United States •Perseverance Research Center, Scottsdale, Arizona, United States •CRI of Arizona, LLC, Sun City West, Arizona, United States •Fiel Family and Sports Medicine PC, Tempe, Arizona, United States •The Institute for Liver Health, Tucson, Arizona, United States •KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States •Applied Rsch Ctr - Arkansas Inc., Little Rock, Arkansas, United States •Smart Cures Clin Research, Anaheim, California, United States •Hope Clinical Research, Canoga Park, California, United States •and 131 more
40	COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection	Completed	Has Results	•COVID-19	•Drug: REGN10933+REGN10987 combination therapy •Drug: Placebo	•Regeneron Study Site, Mesa, Arizona, United States •Regeneron Study Site, Tucson, Arizona, United States •Regeneron Study Site, Canoga Park, California, United States •Regeneron Study Site, Long Beach, California, United States •Regeneron Study Site, Los Angeles, California, United States •Regeneron Study Site, Rolling Hills Estates, California, United States •Regeneron Study Site, San Francisco, California, United States •Regeneron Study Site, Santa Monica, California, United States •Regeneron Study Site, Stanford, California, United States •Regeneron Study Site, Colorado Springs, Colorado, United States •and 47 more
41	A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness	Completed	Has Results	•COVID-19	•Drug: LY3819253 •Drug: LY3832479 •Drug: Placebo	•University of Alabama at Birmingham, Birmingham, Alabama, United States •Arizona Clin Trials-Mesa, Mesa, Arizona, United States •Perseverance Research Center, Scottsdale, Arizona, United States •CRI of Arizona, LLC, Sun City West, Arizona, United States •Fiel Family and Sports Medicine PC, Tempe, Arizona, United States •Orange Grove Banner Clinic, Tucson, Arizona, United States •Arizona Clin Trials-Tucson, Tucson, Arizona, United States •Arkansas Children's, Little Rock, Arkansas, United States •KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States •Applied Rsch Ctr - Arkansas Inc., Little Rock, Arkansas, United States •and 154 more

	Title	Status	Study Results	Conditions	Interventions	Locations
42	Immune Modulators for Treating COVID-19	Completed	No Results Available	•Covid19	•Drug: Infliximab •Drug: Abatacept •Drug: Remdesivir •Drug: cenicriviroc (closed to enrollment as of 3-Sep-2021)	•Banner University Medical Center, Phoenix, Arizona, United States •University of Arkansas Medical Sciences, Little Rock, Arkansas, United States •Scripps Clinical Medical Group, La Jolla, California, United States •UCLA - Ronald Reagan Medical Center, Los Angeles, California, United States •Riverside University, Moreno Valley, California, United States •UC Irvine Medical Center, Orange, California, United States •Stanford University Medical Center, Palo Alto, California, United States •UCLA Medical Center- Santa Monica, Santa Monica, California, United States •Medstar Washington Hospital Center, Washington, District of Columbia, United States •University of Florida-Jacksonville, Jacksonville, Florida, United States •and 81 more
43	COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis	Active, not recruiting	No Results Available	•Covid19	•Drug: Apixaban 2.5 MG •Drug: Placebo	•Valleywise Health Medical Center, Phoenix, Arizona, United States •Dignity Health-St Josephs, Phoenix, Arizona, United States •Central Arkansas Veterans Health Care System, Little Rock, Arkansas, United States •University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States •Stanford University School of Medicine, Palo Alto, California, United States •New Ananda Medical and Urgent Care, Inc., S. El Monte, California, United States •UCSF at Zuckerberg San Francisco General Hospital, San Francisco, California, United States •Mazur and Statner MD PC, Thousand Oaks, California, United States •Torrance Medical Center, Torrance, California, United States •Centura Health Porter Adventist Hospital, Denver, Colorado, United States •and 111 more

	Title	Status	Study Results	Conditions	Interventions	Locations
44	Compassionate Use of Hyperbaric Oxygen Therapy	Enrolling by invitation	No Results Available	•COVID-19		<ul style="list-style-type: none">•White River Wound Healing Center, Batesville, Arkansas, United States•Community Hospital, Monterey, California, United States•Innovative Healing Systems, Tampa, Florida, United States•Decatur Memorial Hospital, Decatur, Indiana, United States•Providence Medical Wound Care Center, Kansas City, Kansas, United States•West Jefferson Medical Center, Marrero, Louisiana, United States•The Wound Treatment Center, Opelousas, Louisiana, United States•Christus Shreveport Bossier Hyperbaric & Wound Care Center, Shreveport, Louisiana, United States•Ascension Providence Rochester Hospital Wound Care Center, Rochester, Michigan, United States•CHI, Chattanooga, Tennessee, United States•Klinika Baromedical, Poznan, Wielkopolskie, Poland
45	Study of Efficacy and Safety of MAS825 in Patients With COVID-19	Completed	Has Results	•COVID-19 Pneumonia, Impaired Respiratory Function	<ul style="list-style-type: none">•Drug: MAS825•Other: Placebo•Drug: Standard of Care (SoC)	<ul style="list-style-type: none">•Novartis Investigative Site, Chula Vista, California, United States•Novartis Investigative Site, Glendale, California, United States•Novartis Investigative Site, Irvine, California, United States•Novartis Investigative Site, La Mesa, California, United States•Novartis Investigative Site, Santa Monica, California, United States•Novartis Investigative Site, Torrance, California, United States•Novartis Investigative Site, Denver, Colorado, United States•Novartis Investigative Site, Washington, District of Columbia, United States•Novartis Investigative Site, Idaho Falls, Idaho, United States•Novartis Investigative Site, Alexandria, Louisiana, United States•and 11 more
46	Treatment for COVID-19 in High-Risk Adult Outpatients	Active, not recruiting	No Results Available	<ul style="list-style-type: none">•COVID-19•SARS-CoV-2	<ul style="list-style-type: none">•Drug: Ascorbic Acid•Drug: Hydroxychloroquine Sulfate•Drug: Azithromycin•Drug: Folic Acid•Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]	<ul style="list-style-type: none">•Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States•Tulane University, New Orleans, Louisiana, United States•Boston University, Boston, Massachusetts, United States•SUNY Upstate Medical University, Syracuse, New York, United States•University of Washington Coordinating Center, Seattle, Washington, United States•UW Virology Research Clinic, Seattle, Washington, United States
47	Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease	Not yet recruiting	No Results Available	•Inflammatory Bowel Diseases	•Biological: COVID-19 Vaccine	<ul style="list-style-type: none">•Mayo Clinic Jacksonville, FL, Jacksonville, Florida, United States•GI Alliance, Baton Rouge, Louisiana, United States•GI Alliance, Cedar Park, Texas, United States•GI Alliance, Southlake, Texas, United States•University of Wisconsin, Madison, Wisconsin, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
48	Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19	Completed	No Results Available	•COVID-19	•Drug: REGN10933+REGN10987 combination therapy •Drug: Placebo	•Regeneron Study Site, Birmingham, Alabama, United States •Regeneron Study Site, Chandler, Arizona, United States •Regeneron Study Site, Phoenix, Arizona, United States •Regeneron Study Site 1, Tucson, Arizona, United States •Regeneron Study Site, Long Beach, California, United States •Regeneron Study Site, Mission Hills, California, United States •Regeneron Study Site, Sacramento, California, United States •Regeneron Study Site, Santa Monica, California, United States •Regeneron Study Site, Stanford, California, United States •Regeneron Study Site, Aurora, Colorado, United States •and 113 more
49	Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)	Terminated	No Results Available	•COVID-19	•Drug: Remdesivir •Drug: RDV Placebo •Drug: Standard of Care	•St. Vincent's Health System, Birmingham, Alabama, United States •UAB Hospital, Birmingham, Alabama, United States •Pulmonary Associates of Mobile, P.C., Mobile, Alabama, United States •St. Joseph Hospital Eureka, Eureka, California, United States •Hoag Memorial Hospital Presbyterian, 16200 Sand Canyon Ave, Irvine, California, United States •Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States •Sutter Medical Center Sacramento, Sacramento, California, United States •Torrance Memorial Medical Center, Torrance, California, United States •MedStar Health Research Institute, Washington, District of Columbia, United States •George Washington Medical Faculty Associates, Washington, District of Columbia, United States •and 53 more
50	EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19	Completed	No Results Available	•COVID-19	•Drug: PF-07321332 •Drug: Ritonavir •Drug: Placebo	•Cahaba Research, Inc., Pelham, Alabama, United States •The Institute for Liver Health dba Arizona Clinical Trials, Mesa, Arizona, United States •The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States •Hope Clinical Research, Canoga Park, California, United States •Ascada Research, Fullerton, California, United States •Atella Clinical Research LLC., La Palma, California, United States •Ark Clinical Research, Long Beach, California, United States •American Institute of Research, Los Angeles, California, United States •South Bay Clinical Research Institute, Redondo Beach, California, United States •Hope Clinical Research (COVID Satellite Site), West Hills, California, United States •and 191 more

	Title	Status	Study Results	Conditions	Interventions	Locations
51	Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults	Active, not recruiting	Has Results	<ul style="list-style-type: none">•COVID-19•SARS-CoV-2	<ul style="list-style-type: none">•Biological: AZD1222•Biological: Placebo	<ul style="list-style-type: none">•Research Site, Phoenix, Arizona, United States•Research Site, Scottsdale, Arizona, United States•Research Site, Little Rock, Arkansas, United States•Research Site, Berkeley, California, United States•Research Site, El Centro, California, United States•Research Site, Los Angeles, California, United States•Research Site, Los Angeles, California, United States•Research Site, San Diego, California, United States•Research Site, San Diego, California, United States•Research Site, San Francisco, California, United States•and 74 more
52	Evaluation of ADG20 for the Prevention of COVID-19	Active, not recruiting	No Results Available	<ul style="list-style-type: none">•COVID-19	<ul style="list-style-type: none">•Drug: ADG20•Drug: Placebo	<ul style="list-style-type: none">•Adagio Investigative Site, Birmingham, Alabama, United States•Adagio Investigative Site, Tucson, Arizona, United States•Adagio Investigative Site, Fayetteville, Arkansas, United States•Adagio Investigative Site, North Little Rock, Arkansas, United States•Adagio Investigative Site, Banning, California, United States•Adagio Investigative Site, Chula Vista, California, United States•Adagio Investigative Site, Culver City, California, United States•Adagio Investigative Site, Escondido, California, United States•Adagio Investigative Site, Fullerton, California, United States•Adagio Investigative Site, Long Beach, California, United States•and 85 more
53	A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults	Recruiting	No Results Available	<ul style="list-style-type: none">•SARS-CoV-2 Infection, COVID-19	<ul style="list-style-type: none">•Biological: Biological/Vaccine: BNT162b2 10mcg•Biological: BNT162b2 20mcg•Biological: BNT162b2 30mcg•Other: Placebo•Biological: Biological/Vaccine: BNT162b2 3mcg	<ul style="list-style-type: none">•University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States•Phoenix Children's Hospital, Phoenix, Arizona, United States•Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States•Matrix Clinical Research, Los Angeles, California, United States•Madera Family Medical Group, Madera, California, United States•Kaiser Permanente Oakland, Oakland, California, United States•Clinical & Translational Research Unit (CTRU) & Spectrum BioBank, Stanford University, Palo Alto, California, United States•Center for Clinical Trials, LLC, Paramount, California, United States•Center for Clinical Trials, Paramount, California, United States•Peninsula Research Associates, Rolling Hills Estates, California, United States•and 117 more

	Title	Status	Study Results	Conditions	Interventions	Locations
54	VIR-7831 for the Early Treatment of COVID-19 in Outpatients	Completed	No Results Available	•Covid19	•Biological: VIR-7831 •Drug: Placebo	•Investigative Site, Anniston, Alabama, United States •Investigative Site, Cullman, Alabama, United States •Investigative Site, Mesa, Arizona, United States •Investigative Site, Tucson, Arizona, United States •Investigative Site, Los Angeles, California, United States •Investigative Site, Los Angeles, California, United States •Investigative Site, Northridge, California, United States •Investigative Site, Oxnard, California, United States •Investigative Site, Rolling Hills Estates, California, United States •Investigative Site, Sacramento, California, United States •and 81 more
55	Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure	Terminated	No Results Available	•COVID-19 •Acute Lung Injury •SARS-CoV-2	•Drug: Dociparstat sodium •Drug: Placebo	•University of Alabama at Birmingham, Birmingham, Alabama, United States •Advanced Pulmonary Research Institute/Wellington Regional Medical Center, Loxahatchee Groves, Florida, United States •Augusta University, Augusta, Georgia, United States •Our Lady of the Lake, Baton Rouge, Louisiana, United States •Tulane University, New Orleans, Louisiana, United States •University Medical Center, New Orleans, Louisiana, United States •William Beaumont Hospital, Royal Oak, Michigan, United States •Wake Forest Baptist Health, Winston-Salem, North Carolina, United States •Texas Health Harris Methodist Hospital Fort Worth, Dallas, Texas, United States •Ascension St. Francis Hospital, Milwaukee, Wisconsin, United States •Ascension All Saints Hospital, Racine, Wisconsin, United States
56	ACTIV-6: COVID-19 Study of Repurposed Medications	Recruiting	No Results Available	•Covid19	•Drug: Ivermectin •Drug: Fluvoxamine •Drug: Fluticasone •Other: Placebo	•Lamb Health, LLC, Gilbert, Arizona, United States •First Care Medical Clinic, Mesa, Arizona, United States •Trident Health Center, Peoria, Arizona, United States •Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States •Assuta Family Medical Group APMC, North Hollywood, California, United States •Stanford, Palo Alto, California, United States •Doctors Medical Group of Colorado Springs, P.C., Colorado Springs, Colorado, United States •Pine Ridge Family Medicine Inc., Colorado Springs, Colorado, United States •Tabitha B. Fortt, M.D., LLC, Stamford, Connecticut, United States •George Washington University Hospital, Washington, District of Columbia, United States •and 84 more

	Title	Status	Study Results	Conditions	Interventions	Locations
57	A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults	Active, not recruiting	No Results Available	•Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19	•Biological: Ad26.COV2.S •Other: Placebo	•Achieve Clinical Research, LLC, Vestavia Hills, Alabama, United States •Hope Research Institute, Phoenix, Arizona, United States •Central Phoenix Medical Clinic, Phoenix, Arizona, United States •Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States •Synexus Clinical Research US, Inc, Tucson, Arizona, United States •Woodland International Research Group, Little Rock, Arkansas, United States •Synexus Clinical Research US, Inc, Cerritos, California, United States •eStudySite, Chula Vista, California, United States •Ark Clinical Research, Long Beach, California, United States •Anthony Mills Medical, Inc, Los Angeles, California, United States •and 115 more
58	Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)	Completed	No Results Available	•Coronavirus Disease 2019 COVID-19	•Drug: TJ003234 •Drug: Placebo	•University of Arkansas, Little Rock, Arkansas, United States •Olive View-UCLA Medical Center, Sylmar, California, United States •Georgetown University Hospital, Washington, District of Columbia, United States •The GW Medical Faculty Associates, Washington, District of Columbia, United States •University of Miami, Miami, Florida, United States •OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States •Indiana University Health, Indianapolis, Indiana, United States •Medpharmics, LLC, Metairie, Louisiana, United States •Ochsner Medical Center, New Orleans, Louisiana, United States •Brigham and Women's Hospital, Boston, Massachusetts, United States •and 4 more

	Title	Status	Study Results	Conditions	Interventions	Locations
59	A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff	Completed	Has Results	<ul style="list-style-type: none">•COVID-19•SARS-CoV2	<ul style="list-style-type: none">•Drug: Bamlanivimab•Drug: Placebo•Drug: Etesevimab	<ul style="list-style-type: none">•Unv of AL Sch of Med Div of Infectious Diseases, Birmingham, Alabama, United States•Care Access Research, Phoenix, Arizona, United States•Allergy and Asthma Clin of NW Ark, Bentonville, Arkansas, United States•Care Access Research LLC, Huntington Beach, California, United States•Alta Bates SMC, Oakland, California, United States•University of Colorado-Anschutz Medical Campus, Aurora, Colorado, United States•NIAID, Miami, Florida, United States•NIAID, Decatur, Georgia, United States•Belmont Village Lincoln Park, Lincoln Park, Illinois, United States•Family Medicine, Indianapolis, Indiana, United States•and 17 more
60	Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19	Completed	No Results Available	<ul style="list-style-type: none">•SARS (Severe Acute Respiratory Syndrome)•Coronavirus	<ul style="list-style-type: none">•Drug: Nitric Oxide Gas	<ul style="list-style-type: none">•University of Alabama, Birmingham, Alabama, United States•Louisiana State University Health Shreveport, Shreveport, Louisiana, United States•Massachusetts General Hospital, Boston, Massachusetts, United States•Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States•Danderyd Sjukhus AB, Danderyd, Stockholm, Sweden
61	CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients	Terminated	No Results Available	<ul style="list-style-type: none">•Covid-19	<ul style="list-style-type: none">•Drug: CPI-006 2 mg/kg + SOC•Drug: CPI-006 1 mg/kg + SOC•Drug: Placebo + SOC	<ul style="list-style-type: none">•Sharp Chula Vista Medical Center, Chula Vista, California, United States•El Centro Regional Medical Center, El Centro, California, United States•Sharp Grossmont Hospital, La Mesa, California, United States•Torrance Memorial Medical Center, Torrance, California, United States•Mayo Clinic - Jacksonville, Jacksonville, Florida, United States•Cambridge Medical Trials, Alexandria, Louisiana, United States•MedPharmics, Metairie, Louisiana, United States•Holy Cross Hospital, Silver Spring, Maryland, United States•Mayo Clinic - Rochester, Rochester, Minnesota, United States•Stony Brook University Medical Center, Stony Brook, New York, United States•and 81 more

	Title	Status	Study Results	Conditions	Interventions	Locations
62	Understanding the Long-term Impact of COVID on Children and Families	Recruiting	No Results Available	•SARS-CoV-2 Infection		<ul style="list-style-type: none">•University of Alabama at Birmingham (Pregnancy Cohort), Birmingham, Alabama, United States•Arkansas Children's Hospital and Research Institute, Little Rock, Arkansas, United States•University of California San Diego, La Jolla, California, United States•Children's Hospital Los Angeles, Los Angeles, California, United States•University of California San Diego Health - Rady Children's Hospital, San Diego, California, United States•University of California San Francisco (Pregnancy Cohort), San Francisco, California, United States•University of California San Francisco, San Francisco, California, United States•Connecticut Children's Medical Center, Hartford, Connecticut, United States•Yale School of Medicine (YSM), New Haven, Connecticut, United States•ChristianaCare Health System, Newark, Delaware, United States•and 55 more
63	Novel Experimental COVID-19 Therapies Affecting Host Response	Recruiting	No Results Available	<ul style="list-style-type: none">•COVID-19•SARS-CoV-2 Infection•Coronavirus Infection	<ul style="list-style-type: none">•Drug: TXA127•Drug: TRV027•Drug: Placebo•Drug: Fostamatinib	<ul style="list-style-type: none">•University of Alabama Birmingham, Birmingham, Alabama, United States•Chandler Regional Medical Center, Chandler, Arizona, United States•Los Angeles County University of Southern California Medical Center, Los Angeles, California, United States•University of Southern California, Los Angeles, California, United States•Cedars-Sinai Medical Center, Los Angeles, California, United States•Ronald Reagan UCLA Medical Center, Los Angeles, California, United States•UCSF Medical Center - Parnassus, San Francisco, California, United States•Stanford University, Stanford, California, United States•University of Colorado Hospital, Aurora, Colorado, United States•Denver Health Medical Center, Denver, Colorado, United States•and 57 more

	Title	Status	Study Results	Conditions	Interventions	Locations
64	A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults # 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2	Active, not recruiting	No Results Available	<ul style="list-style-type: none">•SARS-CoV Infection•Covid19	<ul style="list-style-type: none">•Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)•Other: Placebo (Initial Vaccination Period)•Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)•Other: Placebo (Crossover Vaccination period)•Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)	<ul style="list-style-type: none">•Alabama Clinical Therapeutics, Llc (Pediatric Site), Birmingham, Alabama, United States•Accel Research Sites (Adult Site), Birmingham, Alabama, United States•Central Research Associates, Inc (Pediatric Site), Birmingham, Alabama, United States•The Pain Center of Arizona (Adult Site), Phoenix, Arizona, United States•Foothills Research Center-CCT Research (Pediatric Site), Phoenix, Arizona, United States•Alliance for Multispecialty Research, LLC (Adult Site), Tempe, Arizona, United States•Lynn Institute of the Ozarks (Adult Site), Little Rock, Arkansas, United States•Preferred Research Partners, Inc. (Adult Site), Little Rock, Arkansas, United States•Anaheim Clinical Trials (Adult Site), Anaheim, California, United States•Advanced Clinical Research - Rancho Paseo (Pediatric & Adult Site), Banning, California, United States•and 146 more
65	Expanded Access Treatment Protocol: Remdesivir (RDV: GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)	Approved for marketing	No Results Available	<ul style="list-style-type: none">•SARS-CoV2 Infection	<ul style="list-style-type: none">•Drug: Remdesivir	<ul style="list-style-type: none">•University of Alabama- Birmingham, Birmingham, Alabama, United States•Banner- University Medical Center Phoenix, Phoenix, Arizona, United States•Community Regional Medical Centers (CRMC), Fresno, California, United States•St. Jude Medical Center, Fullerton, California, United States•Scripps Memorial Hospital La Jolla, La Jolla, California, United States•Long Beach Memorial Medical Center, Long Beach, California, United States•Huntington Hospital, Pasadena, California, United States•Scripps Mercy Hospital, San Diego, California, United States•California Pacific Medical Center, San Francisco, California, United States•University of California, Medical Center (Parnassus Campus), San Francisco, California, United States•and 262 more

	Title	Status	Study Results	Conditions	Interventions	Locations
66	Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury	Completed	Has Results	<ul style="list-style-type: none">•COVID-19 Pneumonia•Acute Lung Injury•ARDS	<ul style="list-style-type: none">•Drug: CERC-002•Drug: Placebo	<ul style="list-style-type: none">•Hoag Memorial Hospital, Newport Beach, California, United States•Midway Immunology and Research Center, Fort Pierce, Florida, United States•Triple O Research Institute, P.A., West Palm Beach, Florida, United States•Parkview Research Center, Fort Wayne, Indiana, United States•MedPharmics, LLC, Metairie, Louisiana, United States•LSUHSC - Shreveport, Shreveport, Louisiana, United States•Carolina Institute for Clinical Research, LLC, Fayetteville, North Carolina, United States•Temple University Hospital, Philadelphia, Pennsylvania, United States•AnMed Health Medical Center, Anderson, South Carolina, United States•Lowcountry Infectious Diseases, P.A., Charleston, South Carolina, United States•BRCR Global Texas, McAllen, Texas, United States
67	COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay	Completed	No Results Available	<ul style="list-style-type: none">•Healthy Participants	<ul style="list-style-type: none">•Drug: REGN10933 + REGN10987•Drug: Placebo	<ul style="list-style-type: none">•Regeneron Study Site, Mesa, Arizona, United States•Regeneron Study Site, Tucson, Arizona, United States•Regeneron Study Site, Tucson, Arizona, United States•Regeneron Study Site, La Mesa, California, United States•Regeneron Study Site, La Palma, California, United States•Regeneron Study Site, Long Beach, California, United States•Regeneron Study Site, Los Angeles, California, United States•Regeneron Study Site, Los Angeles, California, United States•Regeneron Study Site, Los Angeles, California, United States•Regeneron Study Site, Montclair, California, United States•and 124 more
68	ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19	Terminated	Has Results	<ul style="list-style-type: none">•COVID-19	<ul style="list-style-type: none">•Drug: BI 764198•Drug: Placebo	<ul style="list-style-type: none">•University of California Irvine, Orange, California, United States•Rapides Regional Medical Center, Alexandria, Louisiana, United States•St. Elizabeth's Medical Center, Boston, Massachusetts, United States•Newton-Wellesley Hospital, Newton, Massachusetts, United States•Mercy Health St. Vincent Medical Center, Toledo, Ohio, United States•Providence Regional Medical Center, Everett, Washington, United States•MultiCare Tacoma General Hospital, Tacoma, Washington, United States•Hospital Luxemburgo, Belo Horizonte, Brazil•IPECC - Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil•Hospital Ernesto Dornelles, Porto Alegre, Brazil•and 15 more

	Title	Status	Study Results	Conditions	Interventions	Locations
69	Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults	Active, not recruiting	No Results Available	•COVID-19	•Drug: AZD7442 •Drug: Placebo	•Research Site, Jasper, Alabama, United States •Research Site, Tucson, Arizona, United States •Research Site, Long Beach, California, United States •Research Site, Northridge, California, United States •Research Site, Cutler Bay, Florida, United States •Research Site, Miami, Florida, United States •Research Site, Miami, Florida, United States •Research Site, Pompano Beach, Florida, United States •Research Site, Chicago, Illinois, United States •Research Site, Lake Charles, Louisiana, United States •and 100 more
70	Adaptive COVID-19 Treatment Trial 4 (ACTT-4)	Completed	Has Results	•COVID-19	•Drug: Baricitinib •Drug: Dexamethasone •Other: Placebo •Drug: Remdesivir	•University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States •UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States •University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States •University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States •University of California Irvine Medical Center - Infectious Disease, Orange, California, United States •VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States •University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States •Kaiser Permanente San Diego Medical Center, San Diego, California, United States •Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States •University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States •and 62 more

	Title	Status	Study Results	Conditions	Interventions	Locations
71	Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants #2 Years	Recruiting	No Results Available	•SARS-CoV-2 Infection, COVID19	•Biological: BNT162b2	<ul style="list-style-type: none"> •University of Chicago Comer Children's Hospital, Chicago, Illinois, United States •University of Chicago Medical Center, Chicago, Illinois, United States •Ochsner Clinic Foundation, Jefferson, Louisiana, United States •Ochsner Medical Center - Jefferson Highway, New Orleans, Louisiana, United States •Henry Ford Health System, Detroit, Michigan, United States •Henry Ford Hospital - Research Pharmacy, Detroit, Michigan, United States •Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States •Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States •Texas Children's Hospital, Houston, Texas, United States •Seattle Children's Research Institute: Building Cure, Seattle, Washington, United States •and 15 more
72	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	Completed	Has Results	•COVID-19	<ul style="list-style-type: none"> •Drug: Sarilumab •Drug: Placebo 	<ul style="list-style-type: none"> •Regeneron Study Site, Los Angeles, California, United States •Regeneron Study Site, Sacramento, California, United States •Regeneron Study Site, Santa Monica, California, United States •Regeneron Study Site, Aurora, Colorado, United States •Regeneron Study Site, Denver, Colorado, United States •Regeneron Study Site, New Haven, Connecticut, United States •Regeneron Study Site, Washington, District of Columbia, United States •Regeneron Study Site, Gainesville, Florida, United States •Regeneron Study Site, Orlando, Florida, United States •Regeneron Study Site, Tampa, Florida, United States •and 52 more
73	Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)	Terminated	Has Results	•COVID-19	<ul style="list-style-type: none"> •Drug: Placebo •Drug: Ruxolitinib 	<ul style="list-style-type: none"> •Honor Health Research Institute, Scottsdale, Arizona, United States •Sharp Memorial Hospital, San Diego, California, United States •Georgetown University Hospital, Washington, District of Columbia, United States •Teradan Clinical Trials, Brandon, Florida, United States •University of Florida, Gainesville, Florida, United States •Tampa General Hospital, Tampa, Florida, United States •University of South Florida, Tampa, Florida, United States •Northshore University Health System, Chicago, Illinois, United States •Loyola University Medical Center, Maywood, Illinois, United States •Indiana University Simon Cancer Center, Indianapolis, Indiana, United States •and 26 more

	Title	Status	Study Results	Conditions	Interventions	Locations
74	Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting	Terminated	Has Results	•COVID-19	•Drug: RDV •Drug: Placebo to Match RDV	•Arizona Liver Health, Chandler, Arizona, United States •Arizona Clinical Trials, Tucson, Arizona, United States •St Joseph Hospital Eureka, Eureka, California, United States •St. Joseph Heritage Healthcare, Fullerton, California, United States •Elevated Health, Huntington Beach, California, United States •Ruane Clinical Research Group, Los Angeles, California, United States •LA Universal Center, INC., Los Angeles, California, United States •Mills Clinical Research, Los Angeles, California, United States •Kaiser Permanente Northern California, Oakland, California, United States •FOMAT Medical Research, Oxnard, California, United States •and 94 more
75	Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation	Completed	Has Results	•COVID-19	•Drug: Remdesivir (RDV) •Drug: Placebo	•The Institute for Liver Health, Mesa, Arizona, United States •The Institute for Liver Health, Tucson, Arizona, United States •Franco Felizarta, MD, Bakersfield, California, United States •Aurora FDRC Inc., Costa Mesa, California, United States •Elevated Health, Huntington Beach, California, United States •Cedars-Sinai Medical Center, Los Angeles, California, United States •Western Clinical Research, Placentia, California, United States •UC Davis Health/Medical Center, Sacramento, California, United States •Bradenton Research Center, Inc., Bradenton, Florida, United States •Integrity Clinical Research, LLC, Doral, Florida, United States •and 18 more
76	The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2	Completed	No Results Available	•COVID-19	•Drug: PUL-042 Inhalation Solution •Drug: Placebo	•University of California Irvine, Orange, California, United States •Premier Urgent Care of California, San Bernardino, California, United States •Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States •Invesclinic US LLC, Fort Lauderdale, Florida, United States •Luminous Cinical Research- South Florida Urgent Care, Miami, Florida, United States •Entrust Clinical Research, Miami, Florida, United States •DBC Research, Tamarac, Florida, United States •Affinity Clinical Research, LLC, Tampa, Florida, United States •Clinical Research Atlanta, Stockbridge, Georgia, United States •Willis-Knighton Physcian Network, Bossier City, Louisiana, United States •and 5 more

	Title	Status	Study Results	Conditions	Interventions	Locations
77	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)	Completed	Has Results	•COVID-19	•Drug: Remdesivir •Drug: Standard of Care	•Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States •Alta Bates Summit Medical Center, Berkeley, California, United States •Mills-Peninsula Medical Center, Burlingame, California, United States •Eden Medical Center, Castro Valley, California, United States •Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States •Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States •St Joseph Hospital Eureka, Fortuna, California, United States •Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States •Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States •Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States •and 173 more
78	Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)	Recruiting	No Results Available	•COVID-19	•Drug: Remdesivir	•Children's Hospital of Alabama, Birmingham, Alabama, United States •Children's Hospital Los Angeles, Los Angeles, California, United States •Ronald Reagan University of California, Los Angeles Medical Center, Los Angeles, California, United States •Valley Children's Hospital, Madera, California, United States •Rady Children's Hospital San Diego, San Diego, California, United States •Tampa General Hospital (Inpatient Visits), Tampa, Florida, United States •Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States •Norton Children's Hospital, Louisville, Kentucky, United States •Tulane University School of Medicine, New Orleans, Louisiana, United States •Johns Hopkins Children's Center, Baltimore, Maryland, United States •and 27 more

	Title	Status	Study Results	Conditions	Interventions	Locations
79	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment	Completed	Has Results	•COVID-19	•Drug: Remdesivir •Drug: Standard of Care	•Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States •Alta Bates Summit Medical Center, Berkeley, California, United States •Mills-Peninsula Medical Center, Burlingame, California, United States •Eden Medical Center, Castro Valley, California, United States •Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States •Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States •St Joseph Hospital Eureka, Fortuna, California, United States •Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States •Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States •Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States •and 174 more
80	COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80	Terminated	Has Results	•COVID-19	•Drug: Apixaban 2.5 MG •Drug: Apixaban 5MG •Drug: Aspirin •Drug: Placebo	•University of Southern California, Los Angeles, California, United States •Stanford University School of Medicine, Palo Alto, California, United States •Zuckerberg San Francisco General, San Francisco, California, United States •Olive View-UCLA Medical Center, Sylmar, California, United States •Pine Ridge Family Medicine, Colorado Springs, Colorado, United States •Life Tree Health, Inc., Washington, District of Columbia, United States •Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States •University of Florida at Gainesville, Gainesville, Florida, United States •Vital Pharma Research, Hialeah, Florida, United States •Advanced Research for Health Improvement, LLC, Immokalee, Florida, United States •and 61 more

	Title	Status	Study Results	Conditions	Interventions	Locations
81	Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection	Active, not recruiting	No Results Available	<ul style="list-style-type: none">•COVID-19•Viral Respiratory Illnesses	<ul style="list-style-type: none">•Drug: Nitazoxanide•Drug: Placebo•Dietary Supplement: Vitamin Super B-Complex	<ul style="list-style-type: none">•HealthStar Research LLC, Hot Springs, Arkansas, United States•So Cal Clinical Research, Huntington Beach, California, United States•Long Beach Clinical Trials, LLC, Long Beach, California, United States•Meris Clinical Research, Brandon, Florida, United States•Invesclinica US LLC, Fort Lauderdale, Florida, United States•The Chappel Group Research, Kissimmee, Florida, United States•New Horizon Research Center, Miami, Florida, United States•Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States•DMI Research, Pinellas Park, Florida, United States•Tampa General Hospital, Tampa, Florida, United States•and 16 more
82	A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19	Completed	No Results Available	<ul style="list-style-type: none">•Mild-to-moderate COVID-19	<ul style="list-style-type: none">•Other: KB109 + Self Supportive Care (SSC)•Other: Self Supportive Care (SSC) Alone	<ul style="list-style-type: none">•Healthstar Research, Hot Springs, Arkansas, United States•Axon Clinical Research, Riverside, California, United States•Medical Center for Clinical Research, San Diego, California, United States•Vista Health Research, Miami, Florida, United States•Bio-Medical Research, Miami, Florida, United States•Mount Vernon Clinical Research, Atlanta, Georgia, United States•Centex Studies, Inc. - Lake Charles, Lake Charles, Louisiana, United States•University of Massachusetts Medical School, Worcester, Massachusetts, United States•Wake Research - Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States•Carolina Institute For Clinical Research, Fayetteville, North Carolina, United States•and 6 more
83	A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection	Terminated	No Results Available	<ul style="list-style-type: none">•Covid19		<ul style="list-style-type: none">•Mayo Clinic, Phoenix, Arizona, United States•Mayo Clinic, Jacksonville, Florida, United States•LSUHSC Shreveport, Shreveport, Louisiana, United States•Henry Ford Health System, West Bloomfield, Michigan, United States•Mayo Clinic, Rochester, Minnesota, United States•Hackensack Meridian Health, Hackensack, New Jersey, United States•Sri Jayadeva, Bengaluru, Karnataka, India•King Edward Memorial Hospital, Mumbai, Maharashtra, India•Gregorio Marañon Hospital, Madrid, Spain•Imperial College, London, England, United Kingdom

	Title	Status	Study Results	Conditions	Interventions	Locations
84	Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)	Completed	No Results Available	<ul style="list-style-type: none"> •COVID-19 •Pneumonia 	<ul style="list-style-type: none"> •Drug: Heparin 	<ul style="list-style-type: none"> •Emory University Hospital Midtown, Atlanta, Georgia, United States •University of Chicago, Chicago, Illinois, United States •Ochsner Clinic, Jefferson, Louisiana, United States •Maine Medical Center, Portland, Maine, United States •Henry Ford University, Dearborn, Michigan, United States •Beaumont Hospital, Royal Oak, Michigan, United States •Mayo Clinic, Rochester, Minnesota, United States •Saint Louis University School of Medicine/Saint Louis Veterans Affairs Medical Center, Saint Louis, Missouri, United States •Cooper University Health Care, Camden, New Jersey, United States •Hackensack University Medical Center, Hackensack, New Jersey, United States •and 50 more
85	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia	Completed	Has Results	<ul style="list-style-type: none"> •COVID-19 Pneumonia 	<ul style="list-style-type: none"> •Drug: Tocilizumab (TCZ) •Drug: Placebo 	<ul style="list-style-type: none"> •University of California San Diego, La Jolla, California, United States •eStudySite, La Mesa, California, United States •David Geffen School of Medicine UCLA, Los Angeles, California, United States •Stanford University, Stanford, California, United States •Denver Health Medical Center, Denver, Colorado, United States •University of Miami Miller School of Medicine, Miami, Florida, United States •Rush University Medical Center, Chicago, Illinois, United States •University of Chicago, Chicago, Illinois, United States •Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States •Baystate Health System, Springfield, Massachusetts, United States •and 52 more
86	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia	Active, not recruiting	Has Results	<ul style="list-style-type: none"> •COVID-19 Pneumonia 	<ul style="list-style-type: none"> •Drug: Placebo •Drug: Tocilizumab 	<ul style="list-style-type: none"> •Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States •Univ of AZ Coll of Med, Tucson, Arizona, United States •El Centro Regional Medical Center, El Centro, California, United States •eStudySite, La Mesa, California, United States •Highland Hospital Oakland, Oakland, California, United States •St. Joseph'S Hospital, Orange, California, United States •San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States •Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States •Miami Veterans Administration Healthcare System - NAVREF, Miami, Florida, United States •University of Miami Pulmonary, Miami, Florida, United States •and 41 more

	Title	Status	Study Results	Conditions	Interventions	Locations
87	Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease	Completed	Has Results	•Covid-19	•Drug: HCQ •Drug: HCQ+AZT •Drug: Placebo	•Novartis Investigative Site, Fullerton, California, United States •Novartis Investigative Site, Los Angeles, California, United States •Novartis Investigative Site, Chicago, Illinois, United States •Novartis Investigative Site, Baton Rouge, Louisiana, United States •Novartis Investigative Site, Baltimore, Maryland, United States •Novartis Investigative Site, Chapel Hill, North Carolina, United States •Novartis Investigative Site, Seattle, Washington, United States
88	A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia	Completed	Has Results	•COVID-19 Pneumonia	•Drug: Remdesivir •Drug: Tocilizumab •Drug: Placebo	•Valleywise Health Medical Center, Phoenix, Arizona, United States •eStudySite - Chula Vista - PPDS, Chula Vista, California, United States •Hoag Hospital Irvine, Irvine, California, United States •Providence St Johns Health Center, Santa Monica, California, United States •Yale University School of Medicine; HIV Clinical Trials Program, New Haven, Connecticut, United States •Medstar Georgetown University Hospital, Washington, District of Columbia, United States •Holy Cross Hospital Inc, Fort Lauderdale, Florida, United States •Larkin Community Hospital Palm Springs Campus (Hialeah), Hialeah, Florida, United States •University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, United States •Larkin Community Hospital, South Miami, Florida, United States •and 44 more
89	Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19	Completed	Has Results	•SARS-CoV-2 Infection, COVID-19	•Drug: Molnupiravir 200 mg •Drug: Molnupiravir 400 mg •Drug: Molnupiravir 800 mg •Drug: Placebo (PBO)	•Valley Clinical Trials, Inc., Northridge, California, United States •FOMAT Medical Research, Oxnard, California, United States •Southern California Emergency Medicine, Yucaipa, California, United States •Indago Research and Health Center, Inc., Hialeah, Florida, United States •NOLA Research Works, LLC, New Orleans, Louisiana, United States •University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States •Duke University Medical Center, Durham, North Carolina, United States •Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States •Care United Research, LLC, Forney, Texas, United States •Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
90	Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)	Terminated	No Results Available	•Coronavirus Disease (COVID-19)	•Drug: Molnupiravir •Drug: Placebo	•Kaiser Foundation Hospital - South Bay (Site 1832), Harbor City, California, United States •Cedars-Sinai Medical Center (Site 1822), Los Angeles, California, United States •University of California Davis Health (Site 1809), Sacramento, California, United States •University Of Florida (Site 1810), Gainesville, Florida, United States •Wellstar Kennestone Hospital (Site 1801), Marietta, Georgia, United States •Loretto Hospital (Site 1838), Chicago, Illinois, United States •LSU-HSC Shreveport (Site 1824), Shreveport, Louisiana, United States •Henry Ford Health System (Site 1821), Detroit, Michigan, United States •University of Mississippi Medical Center (Site 1846), Jackson, Mississippi, United States •University of Nebraska Medical Center (Site 1835), Omaha, Nebraska, United States •and 79 more
91	Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study	Recruiting	No Results Available	•Lower Respiratory Tract Infection •Parainfluenza •Immunocompromised •COVID-19	•Drug: DAS181 •Drug: Placebo •Drug: DAS181 COVID-19 •Drug: DAS181 OL	•City of Hope cancer Center, Duarte, California, United States •UCLA, Los Angeles, California, United States •University of California Davis Health System, Sacramento, California, United States •University of California San Diego Medical Center, San Diego, California, United States •Children's Hospital Colorado, Aurora, Colorado, United States •Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States •University of Chicago, Chicago, Illinois, United States •Loyola University Medical Center, Maywood, Illinois, United States •University of Kansas Medical Center, Fairway, Kansas, United States •Louisiana State University, Shreveport, Louisiana, United States •and 50 more

	Title	Status	Study Results	Conditions	Interventions	Locations
92	ACTIV-3: Therapeutics for Inpatients With COVID-19	Active, not recruiting	No Results Available	•Covid19	<ul style="list-style-type: none">•Biological: LY3819253•Drug: Placebo•Biological: Remdesivir•Biological: VIR-7831•Biological: BRII-196/BRII-198•Biological: AZD7442•Drug: MP0420•Drug: PF-07304814	<ul style="list-style-type: none">•Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue, Tucson, Arizona, United States•Southern Arizona VA Healthcare System (Site 074-009), 3601 S. 6th Ave., Tucson, Arizona, United States•Velocity Chula Vista (Site 080-034), 752 Medical Center Ct., Ste. 304, Chula Vista, California, United States•Community Regional Medical Center (Site 203-005), 2823 Fresno Street, Fresno, California, United States•Velocity San Diego (Site 080-035), 5565 Grossmont Center Drive, Building 2, Suite 1, La Mesa, California, United States•VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street, Loma Linda, California, United States•VA Long Beach Healthcare System (Site 074-026), 5901 East 7th Street (09/151-M2), Long Beach, California, United States•Keck Hospital of USC (Site 301-020), 1500 San Pablo Street, Los Angeles, California, United States•Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd., Los Angeles, California, United States•Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza, Los Angeles, California, United States•and 137 more
93	COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)	Active, not recruiting	No Results Available	•COVID-19	<ul style="list-style-type: none">•Drug: AS03•Biological: BNT162b2•Biological: BNT162b2 (B.1.1.529)•Biological: BNT162b2 (B.1.351)•Biological: CoV2 preS dTM [B.1.351]•Biological: CoV2 preS dTM/D614•Biological: CoV2 preS dTM/D614+B.1.351•Biological: mRNA-1273•Biological: mRNA-1273.351•Biological: mRNA-1273.529•Biological: mRNA-1273.617.2•Other: Sodium Chloride, 0.9%	<ul style="list-style-type: none">•University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic, Birmingham, Alabama, United States•University of California, San Diego - Antiviral Research Center, San Diego, California, United States•Zuckerberg San Francisco General Hospital, UCSF Positive Health Program, San Francisco, California, United States•The George Washington University Medical Faculty Associates - Infectious Diseases, Washington, District of Columbia, United States•Howard University - Department of Medicine - Division of Infectious Disease, Washington, District of Columbia, United States•Morehouse School of Medicine - Clinical Research Center, Atlanta, Georgia, United States•Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States•Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States•University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States•University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States•and 12 more

	Title	Status	Study Results	Conditions	Interventions	Locations
94	Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19	Completed	No Results Available	•Covid19	•Drug: rNAPc2 •Drug: Heparin	•ARCA Investigational Site #119, Fairhope, Alabama, United States •ARCA Investigational Site #118, Phoenix, Arizona, United States •ARCA Investigational Site #120, Tucson, Arizona, United States •ARCA Investigational Site #104, Aurora, Colorado, United States •ARCA Investigational Site #117, Denver, Colorado, United States •ARCA Investigational Site #101, Jacksonville, Florida, United States •ARCA Investigational Site #128, Evanston, Illinois, United States •ARCA Investigational Site #113, New Orleans, Louisiana, United States •ARCA Investigational Site #105, Falls Church, Virginia, United States •ARCA Investigational Site #114, Richmond, Virginia, United States •and 14 more
95	Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE	Recruiting	No Results Available	•Covid19	•Drug: theraputic heparin •Drug: prophylactic heparin •Drug: P2Y12 •Drug: Crizanlizumab Injection •Drug: SGLT2 inhibitor	•University of Alabama, Birmingham, Alabama, United States •University of Arizona, Tucson, Arizona, United States •University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States •Kaiser Permanente Fontana, Fontana, California, United States •Kaiser Permanente Los Angeles, Los Angeles, California, United States •Smidt Heart Institute at Cedars-Sinai, Los Angeles, California, United States •Ronald Reagan UCLA Medical Center, Los Angeles, California, United States •UC San Diego Hillcrest, San Diego, California, United States •Zuckerberg San Francisco General Hospital, San Francisco, California, United States •UCSF San Francisco, San Francisco, California, United States •and 92 more

	Title	Status	Study Results	Conditions	Interventions	Locations
96	Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.	Recruiting	No Results Available	•Covid19	•Drug: Tempol •Other: Placebo	•Pinnacle Research Group, Anniston, Alabama, United States •LA Universal Research, Los Angeles, California, United States •Doral medical Research, Doral, Florida, United States •Sarkis Clinical Trials, Gainesville, Florida, United States •Omega Research Orlando, LLC, Orlando, Florida, United States •IMA Clinical Research, PC, Saint Petersburg, Florida, United States •Sunrise Research Institute, Sunrise, Florida, United States •Center for Respiratory and Sleep Medicine, Greenwood, Indiana, United States •Tandem Clinical Research GI, LLC., Marrero, Louisiana, United States •IMA Clinical Research, PC, Saint Louis, Missouri, United States •and 12 more
97	A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)	Completed	Has Results	•COVID-19	•Drug: Gimsilumab •Drug: Placebo	•Banner University Medical Center, Phoenix, Arizona, United States •HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, United States •HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States •HonorHealth, Scottsdale, Arizona, United States •HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States •Banner University Medical Center, Tucson, Arizona, United States •UCLA Ronald Reagan Medical Center, Los Angeles, California, United States •University of Florida, Gainesville, Florida, United States •Miami Cancer institute, Miami, Florida, United States •Piedmont Healthcare, Atlanta, Georgia, United States •and 23 more

	Title	Status	Study Results	Conditions	Interventions	Locations
98	SARS-CoV-2/COVID-19 Prevalence Study	Completed	No Results Available	•COVID-19		<ul style="list-style-type: none">•Children's Hospital Colorado CRS, Aurora, Colorado, United States•U of Miami, IDRU at Jackson Memorial Hospital CRS, Miami, Florida, United States•The Ponce de Leon Center CRS, Atlanta, Georgia, United States•UIC Project Wish CRS, Chicago, Illinois, United States•New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States•John's Hopkins CRS, Baltimore, Maryland, United States•New Jersey Medical School CRS, Newark, New Jersey, United States•Harlem Prevention, New York, New York, United States•Physicians & Surgeons CRS, New York, New York, United States•Bronx Prevention Center, New York, New York, United States•and 5 more
99	Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)	Recruiting	No Results Available	•Coronavirus Disease (COVID-19)	<ul style="list-style-type: none">•Drug: Molnupiravir•Drug: Placebo	<ul style="list-style-type: none">•Cahaba Research, Inc. (Site 2523), Birmingham, Alabama, United States•The Institute for Liver Health DBA Arizona Clinical Trials (Site 2484), Mesa, Arizona, United States•The Institute for Liver Health DBA Arizona Clinical Trials (Site 2448), Tucson, Arizona, United States•Hope Clinical Research (Site 2400), Canoga Park, California, United States•Carbon Health (Site 2515), Carlsbad, California, United States•UCSF Fresno (Site 2528), Fresno, California, United States•ASCADA Research, LLC (Site 2516), Fullerton, California, United States•Marvel Clinical Research (Site 2490), Huntington Beach, California, United States•National Research Institute (Site 2452), Los Angeles, California, United States•Valley Clinical Trials Inc. (Site 2406), Northridge, California, United States•and 201 more

	Title	Status	Study Results	Conditions	Interventions	Locations
100	Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine	Completed	Has Results	•COVID-19	•Drug: Hydroxychloroquine •Drug: Placebo oral tablet	•Children's Hospital Colorado/University of Colorado Denver, Aurora, Colorado, United States •University of Florida, Gainesville, Florida, United States •University of Florida Jacksonville, Jacksonville, Florida, United States •University of Florida Health Central Florida, Leesburg, Florida, United States •University of Miami Florida, Miami, Florida, United States •Advent Health, Orlando, Florida, United States •University of South Florida, Tampa, Florida, United States •Northwestern Medicine, Chicago, Illinois, United States •Rush University, Chicago, Illinois, United States •University of Iowa, Iowa City, Iowa, United States •and 24 more

46 additional studies not shown